Zentalis Pharmaceuticals Announces Updates Across its Pipeline Including Promising New Interim Clinical Data on ZN-c3 (WEE1i) and ZN-c5 (SERD) and Two Potentially Registrational Trials for ZN-c3, with the First Trial Already Initiated
We look forward to a productive second half of 2021, as we focus on delivering on our milestones across our entire pipeline.
- We look forward to a productive second half of 2021, as we focus on delivering on our milestones across our entire pipeline.
- Updates from our ongoing trials of ZN-c3 continue to support the potential for our WEE1 inhibitor, ZN-c3, to be both first-in-class and best-in-class.
- Overall, the objective response rate (ORR) in the USC population increased from 40% to 43% based on RECIST criteria.
- The Phase 2 monotherapy trial has been initiated and Zentalis may take multiple doses into this study.